Supplementary MaterialsS1 Fig: Total IgG, IgG1 and IgG3 surface expression on mature B cells from Malian children (n = 9) and U. have been described in humans, data in healthy U.S. adults indicates that Th2-polarized, CXCR3-Tfh cells provide superior B cell help [12]. Consistent with the observation that malaria induces short-lived antibody responses, we recently observed that acute febrile malaria in children preferentially activates Th1-polarized PD-1+CXCR3+ Tfh (Tfh-1) cells that exhibit reduced B cell helper function [13], which is in line with several recent studies in mice showing that excessive IFN- suppresses germinal center B cell responses and anti-humoral immunity [14C17]. Taken together, these observations suggest that Th1 cytokines and Tfh-1 cells may play a role in the differentiation of Ethacridine lactate atypical MBCs. Here we conducted ex vivo analyses of immune cells of [fold change (FC) 2.7 (range 1.3C5.5), false discovery rate (FDR) adjusted p value = 1.008 E-10] and (FC 2.2, FDR p = 0.048), and downregulate (FC -2.1, FDR p = 2.733 E-07) and (FC -2.5, FDR p = 1.549 E-15) (Fig 1B). encodes the Th1-lineage defining transcription factor T-bet, which we found is upregulated in B cells of Mouse monoclonal antibody to Keratin 7. The protein encoded by this gene is a member of the keratin gene family. The type IIcytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratinchains coexpressed during differentiation of simple and stratified epithelial tissues. This type IIcytokeratin is specifically expressed in the simple epithelia lining the cavities of the internalorgans and in the gland ducts and blood vessels. The genes encoding the type II cytokeratinsare clustered in a region of chromosome 12q12-q13. Alternative splicing may result in severaltranscript variants; however, not all variants have been fully described malaria-exposed children (n = 15; S2 Table) relative to healthy U.S adults (n Ethacridine lactate = 10) in a bi-modal distribution with approximately 18% of CD19+ B cells expressing intermediate levels of T-bet (T-betint) and 8% expressing high levels of T-bet (T-bethi) (Fig 2A). On average, atypical MBCs as a percentage of total B cells were 12.0% and 2.5% for Malian children and U.S. subjects, Ethacridine lactate respectively. Ethacridine lactate Among T-bethi B cells, 83.5% were atypical MBCs (95% CI: 80.6C86.3) and 12.0% were activated MBCs (95% CI: 9.3C14.6) (Fig 2B). Conversely, 79.8% of atypical MBCs (95% CI: 74.1C85.5) were T-bet+ and of these 63.3% were T-bethi (95% CI: 56.2C70.4). Moreover, in an independent experiment (n = 10 Malian children) T-bethi B cells of malaria-exposed children expressed markers that are known to be associated with atypical MBCs, with higher surface expression of FCRL5, CD11c, CXCR3 and CD95, and decreased expression of CD35, CD40, CXCR5 and CCR7 [5, 18] (Fig 3). Additionally, FCGR2B, a receptor known to reduce antibody production in B cells, was also upregulated in T-bethi B cells in an independent set of samples (n = 7 Malian children) (Fig 4). Consistent with this, T-bethi B cells exhibited lower phosphorylation of B cell receptor (BCR) signaling molecules following BCR cross-linking (Fig 5A)a functional feature of atypical MBCs described previously.[5] Moreover, within CD21-CD27- atypical MBCs, T-bet expression correlated inversely with phosphorylation of BCR signaling molecules (Fig 5B). Open in a separate window Fig 1 Malaria-associated atypical MBCs upregulate test with Bonferroni corrections for multiple comparisons where appropriate. ****test with Bonferroni corrections for multiple comparisons where appropriate. ****test with Bonferroni corrections for multiple comparisons where appropriate. ****test with Bonferroni corrections for multiple comparisons where appropriate. ****test with Bonferroni corrections for multiple comparisons where appropriate. ****test with Bonferroni corrections for multiple comparisons where appropriate. Paired Students test and Pearson correlation were used for correlative analyses. ****test with Bonferroni adjustments where appropriate. ****test with Bonferroni adjustments where appropriate. ****test with Bonferroni adjustments where appropriate. ****test with Bonferroni adjustments where appropriate. ****test with Bonferroni adjustments where appropriate. ****test with Bonferroni adjustments. ****expression was upregulated in CD21-/lo B cells [30]. Similarly, transcriptome analysis of CD19+ B cells isolated from individuals with systemic lupus erythematosus revealed increased expression compared to CD19+ B cells of healthy controls.[31] Importantly, HIV and malaria-associated atypical MBCs exhibit markedly reduced cytokine and antibody production capacity [4, 5, 32], whereas T-bet+ CD19+ B cells in individuals with autoimmune diseases can produce proinflammatory cytokines and autoreactive antibodies [33C35]. Therefore, T-bet+ B cells that arise in humans in the context of chronic infections versus autoimmunity may differ phenotypically and functionally, although further studies are needed to determine if this is a consistent pattern. That IFN- drives T-bet expression in activated human B cells is consistent with prior studies in mouse.
